The U.S. FDA approved Eli Lilly’s oral GLP-1 receptor agonist orforglipron, marketed as Foundayo, setting up direct commercial competition with Novo Nordisk’s oral obesity pill Wegovy. The approval adds a second once-daily oral option in the expanding anti-obesity market while reducing reliance on injections for some patients. Regulators cleared Foundayo for adults with obesity or overweight plus at least one weight-related comorbidity, in combination with diet and increased physical activity. Lilly is preparing to launch soon after approval. In parallel, coverage of the approval emphasized the market impact of oral convenience—potentially shifting insurer, telehealth, and cash-pay access dynamics as both companies race to broaden adoption. The approvals also come amid heightened scrutiny of GLP-1 product differentiation and comparative messaging in the U.S.